TY  - JOUR
T1  - Andrographis Paniculata        in the Nanotechnology Era: A Review of Therapeutic Benefits and Novel Formulations
A1  - Nagarajan Srinivasan
JF  - International Journal of Pharmaceutical And Phytopharmacological Research
JO  - Int J Pharm Phytopharmacol Res
SN  - 2250-1029
Y1  - 2024
VL  - 14
IS  - 2
DO  - 10.51847/NirOCCzavl
SP  - 12
EP  - 23
N2  - Andrographis paniculata (Burm. f.) Nees, (AP) a traditional medicinal plant, treats various conditions such as microbial infections, diabetes, liver disorders, and cancer. The AP's key diterpenoid, andrographolide (AG), accounts for its major therapeutic properties. The use of AP extracts and their bioactive components in treatments is limited because they have low solubility, are quickly metabolized, and followed by less effective in the body. New ways of delivering drugs, called novel drug delivery systems (NDDS), have been developed. Herbal nanoformulations, comprising natural herbal extracts or bioactive components at a nanoscale size, offer distinct advantages over conventional formulations, such as improved bioavailability and minimized toxicity risk. Some of these systems are nanoparticles, liposomes, phytosomes, niosomes, and lipid nanoparticles. This review summarizes research conducted between 2003 and 2023 on the use of AP extracts and their bioactive components in nanoformulations. It will also discuss recent advances in nanoformulations that make targeting specific therapeutic conditions more precise.
UR  - https://eijppr.com/article/andrographis-paniculata-in-the-nanotechnology-era-a-review-of-therapeutic-benefits-and-novel-zq3sgzggjehuvl7
ER  -